Spherity Blog

In the W3C Verifiable Credentials (VC) community, concerns arose about privacy and consent, focusing on how VCs differ when used by individuals privately (X2I) versus as employees (X2E).

In May 2025, the Louisiana Board held its second public drug verification exercise—testing VRS, DSCSA Authority & ATP credentials ahead of the May 27 DSCSA exemption deadline. How did it compare to the first? What key insights did participants share?

Spherity has achieved the EcoVadis Gold Medal for the second year in a row, placing the company among the top five percent of enterprises evaluated globally for sustainability performance.

DSCSA enforcement is finally here after multiple delays, and ATP credentials are essential for compliance, data protection, and cybersecurity. So, how is ATP credential adoption progressing — and where do we stand today?

As the pharma industry moves toward DSCSA compliance, the VRS Provider Network highlights concerns with GLN Allow Lists and how ATP digital credentials address them.

PDG and FDA hosted the first of three DSCSA town halls—explore key points, industry insights, and key takeaways from the session.

Pharma industry updates and key takeaways from the 15th Annual Pharma Serialization & Supply Chain 2025 and HDA DMC 2025.

Executive Summary Trust across jurisdictions remains a global challenge. Current frameworks lack consistency and interoperability, making it difficult to establish trust in international supply chains and industrial ecosystems. The European Commission’s Competitiveness Compass , introduced by Ursula von der Leyen in January 2025, outlines key actions to strengthen Europe’s economic and technological leadership. A major initiative within this framework is the European Business

Spherity is honored as Digital Identity Solution of the Year 2025 by Enterprise Security Magazine, recognizing our impact and innovation.